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1. INTRODUCTION
jj Burkholderia cepacia complex (BCC) is a group of more than 17 closely related gram- 
negative bacteria species (Table 1).
jj BCC is common in the environment (soil, water, rotting vegetation) and can contaminate 
industrial water sources. 
jj Generally, BCC is a human pathogen only in patients with CF and chronic granulomatous 
disease. 
jj BCC bacteria encode a wide range of virulence mechanisms and are inherently resistant 
to antibiotics. 
2. EPIDEMIOLOGY
jj Overall prevalence in CF patients is 2-4% and is decreasing due to better infection control 
measures reducing person-to-person transmission.
jj Most common species of BCC seen in CF are B. multivorans and B. cenocepacia. 
jj Generally, BCC is associated with increased mortality including for patients who had a lung 
transplantation but prognosis differs for different BCC species and strains. BCC search 
should be routinely done in sputum cultures of CF patients (performed by most 
 microbiology laboratories collaborating with CF centers). 
js BCC search requires specific culture media and can identify only the complex (i.e. BCC).
js Identification of species and strain requires molecular typing (PCR, MLST, PFGE).
jj It is essential to determine the BCC species involved because virulence may 




B. cenocepacia is associated with worse outcomes, especially following lung transplan-
tation and some B. cenocepacia strains (e.g. ET-12, CZI) may confer a higher mortality 
risk than others.
Some strains (e.g. B. nociception and multivorans) can cause acute deterioration with 
life threatening pneumonia and bacteriemia, called “cepacia syndrome”.
jj BCC may spread to susceptible patients through person-to-person contact, contaminated 
surfaces/material or the environment (see also Chapter “Infection control ”).
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Table 1: B. cepacia complex species (adapted from1)
Species Comments
B. cepacia Seen in CF and non-CF patients. Associated with “cepacia syndrome”
B. multivorans Seen in CF and non-CF patients. May be transient. Less  commonly 
associated with “cepacia syndrome”
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B. cenocepacia Seen in CF and non-CF patients. B. cenocepacia IIIA includes 
 ET-12 and CZI strains and B. cenocepacia IIIB includes PHDC and 
Midwest clones. Associated with multiple outbreaks and “cepacia 
syndrome”.
B. stabilis Seen in CF and non-CF patients
B. vietnamiensis Seen in CF and non-CF patients
B. dolosa Seen in CF only. Associated with outbreak in CF clinic. Associated 
with “cepacia syndrome”
B. ambifaria Seen in CF and non-CF patients
B. anthina Seen in CF and non-CF patients
B. pyrrocinia Seen in CF only
B. ubonensis Seen in non-CF patients only
B. latens Seen in CF only
B. diffusa Seen in CF and non-CF patients
B. arboris Seen in CF and non-CF patients
B. seminalis Seen in CF and non-CF patients
B. metallica Seen in CF only
B. contaminans Seen in CF only. It can contaminate pharmaceutical products (e.g 
through contamination of compounding pharmacies) and cause 
outbreaks.
B. lata Seen in CF and non-CF patients
Selective techniques (e.g. mass spectrometry MALDI-TOF) are used for the detection of BCC.
Of note, from a taxonomy point of view, B. gladioli is not considered a member of the BCC 
but can cause infection in CF and non-CF patients
3. CLINICAL MANIFESTATIONS
jj BCC-positive CF patients may present with 
js Colonization without change in pulmonary status.
js Infection with accelerated pulmonary decline.
js Cepacia syndrome (acute deterioration, life threatening pneumonia and bacteriemia).
jj Cepacia syndrome
js Mostly due to B. cenocepacia and more rarely to B. cepacia and B. multivorans infection. 
js Cepacia syndrome may occur at time of acquisition of BCC or after many years.  
js Patients usually present with fever, leukocytosis, increased inflammatory markers 
(C-reactive protein, ESR), patchy infiltrates or cavitary lesions on imaging. 
js Growth of B. cepacia species in sputum and blood cultures may take several days (initial 
cultures may be negative or grow other pathogens). A high clinical suspicion should 
lead to early and aggressive treatment, even before microbiological  diagnosis 
is obtained knowing the high mortality rate of cepacia syndrome.
js Mortality with cepacia syndrome is very high (almost 100%).   
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4. ERADICATION
jj When a culture is positive with BCC for the first time, eradication is often attempted 
although there are no studies to prove effectiveness of this strategy.
jj Some species of BCC (e.g. B multivorans) are transient and sputum culture may only be 
intermittently positive. Infection control guidelines suggest that this does not mean that the 
organism has been eradicated. 
5. PREVENTION
jj Prevention of BCC infection is crucial because of high level antibiotic resistance of these 
pathogens and because of their effect on morbidity and mortality.
jj Most CF centers practice segregation to reduce the risk of transmission between CF 
patients in the hospital environment. 
js Hospitalized patients should always be isolated strictly (contact and droplet isolation). 
js In outpatient clinics, BCC-positive patients should be seen on different days than 
BCC-negative patients or at the end of the consultation program. 
js It has also been recommended that patients infected with B. cenocepacia should be 
separated from patients infected with another BCC species because B. cenocepacia 
may replace another species such as B. multivorans.
6. TREATMENT
jj There are no randomized or quasi randomized controlled studies of the treatment of BCC 
so guidelines for therapy are empiric. 
jj BCC species exhibit innate resistance to many classes of antibiotics and this renders their 
treatment particularly challenging.
jj Antibiotic treatment should be aggressive, combining multiple antibiotics because 
Burkholderia strains are highly resistant. The administration of high doses of antibiotics 
with therapeutic drug monitoring (to reach trough levels above the MIC) is recommended. 
Combination of ≥ 2 antibiotics based on in vitro sensitivity is advocated.
jj Synergy assays for selecting the best antibiotic combination have not been shown 
to  improve outcomes but may provide approach to combining antibiotics in therapy. If 
such a test was to be considered, it should be discussed with the infectious diseases 
consultant.
jj Duration of treatment is not known, but aim to treat until there is clinical response and 
inflammatory markers back to baseline and this may take longer than the usual 14 days 
of therapy.
jj Based on several reviews and case studies, some protocols may be proposed (depending 
on in vitro sensitivity). These protocols are presented in Table 2. Used antibiotics and their 
dosage are presented in Table 3.
jj It is also important to treat other aspects of CF that may hinder response to antibiotic 
 therapy (such as blood glucose control in patients with CF-related diabetes).
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Table 2: Examples of treatment protocols for B. cepacia complex infection 
(adapted from1-5)
Protocol 11 1st Line TMP/SMX, meropenem, and/or ceftazidime
2nd Line Minocycline or tigecycline, ciprofloxacin, piperacillin- 
tazobactam, ticarcillin-clavulanate, chloramphenicol
Combine ≥ 2 agents of 1st line or 2nd line
In severe cases consider:
Meropenem + ceftazidime + ciprofloxacin + minocycline + inhaled 
tobramycin
Protocol 22 TMP/SMX + minocycline for mild cases
3rd line4 Aztreonam or temocillin in combination with other agents have been 
proposed
Table 3: Antibiotics for B. cepacia complex in CF patients (adapted from2,5-8)
Antibiotic Dosage Comments
IV Meropenem 2 g every 8h Maximum 6 g/24h
TDM may be useful





4.5 g every 6-8h Maximum 16 g/24h (of piperacillin)
Tigecycline 100 mg at first dose 
followed by 50 mg every 
12h
Aztreonam 2g every 6-8h
Amikacin 7.5-15 mg/kg every 12h Maximum 1.5g/24h
TDM is required
Tobramycin* 7-10 mg/kg every 24h Maximum 660 mg/24h
TDM is required
Chloramphenicol 1 g  every 6h Not available in Switzerland. 
Risk of aplastic anemia
Temocillin 1-2 g every 12h Not available in Switzerland. 
Risk of cross-reactivity with penicillin 
and cephalosporin. 
Oral TMP/SMX 160/800 mg every 8h
320/1600 mg every 12h
Doxycycline 100 mg every 12h
(continued)
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Minocycline 100 mg every 12h
Ciprofloxacin 750 mg every 12h Up to 750 mg every 8h
Inhaled Meropenem 250 mg diluted in 5 ml of 
NaCl 0.9% every 12h
Based on case reports and on our 
experience (off-label use)
Tobramycin 300 mg every 12h
IV: intravenous, TMP/SMX : trimethroprim/sulfamethoxazole, TDM: therapeutic drug 
 monitoring (see also Chapter “Therapeutic drug monitoring ”)
* Since sputum levels of tobramycin when given IV are not high enough to effectively treat BCC, this route should 
not be preferred but can be combined with inhaled tobramycin in case of “cepacia syndrome”
7. TREATMENT OF “CEPACIA SYNDROME”
jj Treatment protocols for cepacia syndrome are derived from case reports found in 
the recent literature. Some of them are summarized in Table 4. The optimal long-term 
management and antibiotic treatment of cepacia syndrome survivors is unclear.
jj Although the effect of immunosuppressive drugs (corticosteroids, cyclosporine) has not 
been studied in this setting, they are often added to the combination of antibiotics to 
 decrease the inflammatory host response. 
Table 4: Treatment protocols used for Cepacia syndrome (adapted from9-12 )
Protocol based on Regimen 
Adult patient, 
non-transplanted12
Meropenem + tobramycin IV + TMP/SMX IV + chloramphenicol 
+ prednisolone (30-40 mg) + cyclosporine 50 mg IV 1x/day for
5 days then 50 mg orally 1x/day
At discharge (after 35 days): inhaled meropenem + cyclosporin
Adult patient, 
5 years after liver/pancreas 
transplantation10
Meropenem IV + tobramycin IV + TMP/SMX IV + temocillin + 
inhaled meropenem + inhaled tobramycin
At discharge (after 50 days): inhaled meropenem and 
tobramycin 
Pediatric patients (n=2)9 Case 1: ceftazidime + meropenem + ciprofloxacine + chlo-
ramphenicol + TMP/SMX + methylprednisolone 
Case 2: ceftazidime + tobramycine + TMP/SMX + inhaled 
tobramycine + rhDNase  
Our experience Meropenem + ceftazidime IV and inhaled + tobramycin IV + 
TMP/SMX oral + minocycline + tigecycline + prednisone  
(20 mg/day) for 6 weeks
8. B. CENOCEPACIA AND LUNG TRANSPLANTATION
jj Because mortality following lung transplantation was unacceptably high in CF patients 
infected with B. cenocepacia, some transplantation centers considered B. cenocepacia 
infection a contraindication for lung transplantation (Cepacia UK). 
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jj However, in a French study (Boussaud et al. 2008), about 30% of patients infected with 
B. cenocepacia did survive following lung transplantation and non-cenocepacia species
did not seem to confer an increased risk of mortality. Another study (Murray et al. 2008) has 
shown that post-transplant mortality risk may differ with different strains of B. cenocepacia.
jj At the time of writing, in Zurich Lung Transplantation Center, infection with B. cenocepacia 
is considered an absolute contraindication for lung transplantation. At the CURT (Centre 
Universitaire Romand de Transplantation) the inclusion in the waiting list for lung transplan-
tation of a CF patient colonized by B. cenocepacia is discussed on a case-by-case basis 
(see also Chapter “Transplantation ”).
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